Drug search by name

Verapamil Intravenous and Renal dysfunction

Result of checking the interaction of drug Verapamil Intravenous and disease Renal dysfunction for safety when used together.

Check result:

Verapamil Intravenous <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine. The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug. Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation. Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.

References:

Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983): 113-24
McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985): b30-40
"Product Information. Calan (verapamil)." Searle, Skokie, IL.
Pritza DR, Bierman MH, Hammeke MD "Acute toxic effects of sustained-release verapamil in chronic renal failure." Arch Intern Med 151 (1991): 2081-4
Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991): 830-7
Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986): 425-49
Storstein L, Larsen A, Midtbo K, Saevareid L "Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients." Acta Med Scand Suppl 681 (1984): 25-30
Vazquez C, Huelmos A, Alegria E, Errasti P, Purroy A "Verapamil deleterious effects in chronic renal failure." Nephron 72 (1996): 461-4
Mooy J, Schols M, Baak MV, et al "Pharmacokinetics of verapamil in patients with renal failure." Eur J Clin Pharmacol 28 (1985): 405-10

Verapamil Intravenous

Generic Name: verapamil

Brand Name: Calan, Calan SR, Isoptin SR, Verelan, Isoptin, Isoptin IV, Covera-HS, Verelan PM

Synonyms: Verapamil (Intravenous)

What is Verapamil Intravenous?